Poster Session C - Monday Afternoon
Category: IBD
Abdul S. Mohammed, MD
Cleveland Clinic
Orlando, FL
Factors | Ustekinumab N = 510 (%) | Vedolizumab N = 850 (%) | Odds ratio (95% confidence interval), P value |
Age | |||
Adults (18-65y) | 460 (90%) | 710 (84%) | 1.81 (1.28-2.55), 0.0007 |
Seniors ( >65y) | 50 (10%) | 140 (16%) | 0.55 (0.39-0.77), 0.0007 |
Race | |||
White | 460 (90%) | 760 (89%) | 1.08 (0.75-1.56), 0.64 |
Non-white | 50(10%) | 90 (11%) | 0.91 (0.63-1.32), 0.64 |
Gender | |||
Female | 300 (59%) | 460 (54%) | 1.21 (0.97-1.51), 0.90 |
Male | 210 (41%) | 390 (46%) | 0.82 (0.66-1.03), 0.90 |
Clinical characteristics | |||
Tobacco user (current and former) | 490 (96%) | 820 (96%) | 0.89 (0.50-1.59), 0.71 |
Clostridium difficile infection | 70 (14%) | 150 (18%) | 0.74 (0.54-1.01), 0.05 |
Small bowel obstruction | 10 (2%) | 30 (4%) | 054 (0.26-1.12), 0.10 |
Fistula of intestine | 230 (45%) | 330 (38%) | 1.29 (1.03-1.61), 0.02 |
Anorectal fistula | 150 (20%) | 230 (27%) | 1.12 (0.88-1.43), 0.34 |
Perianal abscess | 100 (20%) | 140 (16%) | 1.23 (0.93-1.64), 0.14 |
Anorectal abscess | 80 (16%) | 130 (15%) | 1.03 (0.76-1.39), 0.84 |
Neoplasm of colon | 70 (14%) | 160 (19%) | 0.68 (0.54-0.93), 0.01 |
Malignant neoplasm of colon | 10 (2%) | 30 (4%) | 0.54 (0.26-1.12), 0.10 |